Education
About Us
Working with TipRanks
Follow Us
Camurus AB (SE:CAMX)
:CAMX
CAMX Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr483.80 - kr754.50
Previous CloseN/A
Volume19.01K
Average Volume (3M)87.04K
Market Cap
$41.06B
Enterprise Valuekr33.13B
Total Cash (Recent Filing)$3.35B
Total Debt (Recent Filing)$103.80M
Price to Earnings (P/E)56.2
Beta0.77
Next Earnings
Nov 06, 2025EPS Estimate
3.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.08
Shares Outstanding59,848,633
10 Day Avg. Volume76,491
30 Day Avg. Volume87,040
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue14.62
Enterprise Value/Gross Profit15.63
Enterprise Value/Ebitda35.43
Forecast
1Y Price Target
$702.68Price Target Upside2.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Camurus AB News
CAMX FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was kr483.80 and its highest was kr754.50 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is $41.06B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is Nov 06, 2025 which is in 31 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on Jul 17, 2025. The company reported kr4.08 earnings per share for the quarter, beating the consensus estimate of kr3.419 by kr0.661.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Undervalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 3.53.
How many shares outstanding does Camurus AB have?
Camurus AB has 59,848,633 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of kr4.08 in its last earnings report, beating expectations of kr3.419. Following the earnings report the stock price went up 0.58%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in SE:CAMX
Company Description
Camurus AB
Camurus AB (CAMX) is a Swedish biotechnology company focused on developing and commercializing innovative drug delivery technologies and products for the treatment of various severe and chronic diseases, particularly in the fields of pain management and addiction. The company leverages its proprietary FluidCrystal® technology platform to create long-acting injectable formulations, enhancing patient adherence and improving therapeutic outcomes. Camurus' core products include Buvidal, an injectable formulation for the treatment of opioid dependence, and other pipeline candidates targeting different therapeutic areas.
CAMX Company Deck
CAMX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong financial performance and growth in key product sales, along with a solid cash position. However, challenges such as the FDA's CRL and increased operating expenses were noted. The positive aspects of growth and profitability were more pronounced, leading to an optimistic outlook.View all SE:CAMX earnings summariesCAMX Stock 12 Month Forecast
Average Price Target
kr702.68
▲(2.43% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
BioArctic AB Class B
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Options Prices
Currently, No data available
---